HCPCS code J0217 — Inj velmanase alfa-tycv 1 mg. Status: Active. Effective Jan 1, 2024. Source: CMS HCPCS Level II.

J0217

Active

Inj velmanase alfa-tycv 1 mg

Injection, velmanase alfa-tycv, 1 mg

Category: Drugs
Section: J-codes: Drugs Administered Other Than Oral Method
Effective: Jan 1, 2024
Code type: alphanumeric
OPPS Status: G — Pass-through drugs and biologicals
OPPS APC: 0710

MUE — Medically Unlikely Edits

Maximum units of J0217 Medicare will pay for one beneficiary on one date of service. Claims exceeding the MUE are denied or returned for review.

Service Type Max Units / Day
DME Supplier 0
Outpatient Hospital 150
Practitioner Services 150

Source: CMS Medicare NCCI Medically Unlikely Edits

NDC Crosswalk

National Drug Codes (NDCs) mapped to this HCPCS code.

NDC Drug Name
10122-0180-02 Lamzede

Change History

Quarterly changes published by CMS. Revisions may affect the code description, coverage, or rate — review each quarter's changes before submitting claims.

  • New Code 2024-Q1
    Inj velmanase alfa-tycv 1 mg